ASCO 2014: Dr. Jeffrey A. Sosman gives his top picks in melanoma research

1. Abstract LBA 9000, Antoni Ribas et al.

Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).

http://abstracts.asco.org/144/AbstView_144_133842.html

2. Abstract LBA 9008, Alexander M. Eggermont et al. Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial.

http://abstracts.asco.org/144/AbstView_144_130118.html

3. Abstract 9011, Georgina V. Long et al.

COMBI-d: A randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF^V600E/K mutation-positive cutaneous melanoma.

http://abstracts.asco.org/144/AbstView_144_128598.html

4. Abstract 9008a, Howard L. Kaufman et al.

Primary overall survival (OS) from OPTiM, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.

http://abstracts.asco.org/144/AbstView_144_133898.html

5. Abstract 9010, Keith Flaherty et al.

Updated overall survival (OS) for BRF113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D+T) in pts with BRAF V600 mutation-positive (+) metastatic melanoma (MM).

http://abstracts.asco.org/144/AbstView_144_134903.html

Dr. Jeffrey A. Sosman is professor of medicine and Ingram Professor for Cancer Research, Vanderbilt University Medical Center, Nashville, Tenn.

1. Abstract LBA 9000, Antoni Ribas et al.

Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).

http://abstracts.asco.org/144/AbstView_144_133842.html

2. Abstract LBA 9008, Alexander M. Eggermont et al. Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial.

http://abstracts.asco.org/144/AbstView_144_130118.html

3. Abstract 9011, Georgina V. Long et al.

COMBI-d: A randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF^V600E/K mutation-positive cutaneous melanoma.

http://abstracts.asco.org/144/AbstView_144_128598.html

4. Abstract 9008a, Howard L. Kaufman et al.

Primary overall survival (OS) from OPTiM, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.

http://abstracts.asco.org/144/AbstView_144_133898.html

5. Abstract 9010, Keith Flaherty et al.

Updated overall survival (OS) for BRF113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D+T) in pts with BRAF V600 mutation-positive (+) metastatic melanoma (MM).

http://abstracts.asco.org/144/AbstView_144_134903.html

Dr. Jeffrey A. Sosman is professor of medicine and Ingram Professor for Cancer Research, Vanderbilt University Medical Center, Nashville, Tenn.

1. Abstract LBA 9000, Antoni Ribas et al.

Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).

http://abstracts.asco.org/144/AbstView_144_133842.html

2. Abstract LBA 9008, Alexander M. Eggermont et al. Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial.

http://abstracts.asco.org/144/AbstView_144_130118.html

3. Abstract 9011, Georgina V. Long et al.

COMBI-d: A randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF^V600E/K mutation-positive cutaneous melanoma.

http://abstracts.asco.org/144/AbstView_144_128598.html

4. Abstract 9008a, Howard L. Kaufman et al.

Primary overall survival (OS) from OPTiM, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.

http://abstracts.asco.org/144/AbstView_144_133898.html

5. Abstract 9010, Keith Flaherty et al.

Updated overall survival (OS) for BRF113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D+T) in pts with BRAF V600 mutation-positive (+) metastatic melanoma (MM).

http://abstracts.asco.org/144/AbstView_144_134903.html

Dr. Jeffrey A. Sosman is professor of medicine and Ingram Professor for Cancer Research, Vanderbilt University Medical Center, Nashville, Tenn.